InnovationRx: Chelsea Clinton Invests In 24/7 Pediatrics Startup
Plus: Electronic health record company Veradigm’s $140 million AI gamble on startup ScienceIO.
Source: forbes.com
📰 March Ventures News
March Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from March Ventures. Real-time updates on events, politics, business and more.
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board
BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory
Source: eagletribune.com
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
Life sciences veteran’s experience leading R&D organizations and bringing more than 25 products to market will support Volastra’s growing pipeline of treatments targeting chromosomally unstable cancersNEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the...
David Nicholson Olivier Elemento Lewis Cantley Samuel Bakhoum Sandi Peterson Volastra Therapeutics Inc
Source: pharmiweb.com
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
NEW YORK--(BUSINESS WIRE)--Oct 30, 2023--
Source: eagletribune.com
bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the w
CRISPR-Ready ioGlutamatergic Neurons™ are first-in-class stem-cell derived human neurons containing a constitutively-expressed Cas9 nuclease for gene knockouts and CRISPR screens.New cell type creates an opportunity for research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons;...
Source: pharmiweb.com
Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies
/PRNewswire/ -- Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company...
United Kingdom Prnewswire Synthego Paul Dabrowski Mark Kotter National Resilience University Of Cambridge
Source: prnewswire.com
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies
Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well ...
Source: pharmiweb.com
bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease
Cell coding company bit.bio announces an expansion to its product portfolio to accelerate research into neurodegenerative diseases. Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)
United Kingdom Hermann Hauser Kostenloser Wertpapierhandel Mark Kotter Farah Patell Socha Alan Roemer
Source: finanznachrichten.de
Colossal Raises $60M in Series A Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com